Persistent-relapsing SARS-CoV-2 infection following rituximab treatment for autoimmune rheumatic diseases: diagnosis and outcomes

Persistent-relapsing SARS-CoV-2 infection following rituximab treatment for autoimmune rheumatic diseases: diagnosis and outcomes

Background COVID-19 may persist or relapse in patients on B-cell depleting biologic therapies.Objective To examine the rate and outcome of persistent-relapsing COVID-19 (prCOVID-19) in patients with autoimmune rheumatic diseases (AIRD) treated with rituximab (RTX).Methods Single-centre, retrospectiv...

Full description

Saved in:
Bibliographic Details
Main Authors: Antonis Fanouriakis, Katerina Chavatza, Emmanouil Karofylakis, Konstantinos Thomas, Elisavet Mastrostamati, Charalampos Charalampidis, Elvira-Markela Antonogiannaki, Ioannis Grigoropoulos, Foteini Gkolemi, Georgios Koromvokis, Electra Kalara, Eleni Sambatakaki
Format: Article
Language:English
Published: BMJ Publishing Group 2025-07-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/11/3/e005756.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://rmdopen.bmj.com/content/11/3/e005756.full

Similar Items